BOSTON, Nov. 5 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global biopharmaceutical services provider, announced today that it has established The Expert Office(TM) at PAREXEL. The Expert Office, which provides a single point of contact for clients to more quickly access PAREXEL’s comprehensive worldwide expertise, aligns the Company’s leading medical, therapeutic area, regulatory, and clinical operations experts with their counterparts at biopharmaceutical companies. The Expert Office supports PAREXEL in delivering a new level of strategic partnering based on program design expertise, operational excellence, and project leadership.
“Biopharmaceutical companies face myriad regulatory, medical, and scientific issues that are changing the clinical development environment, and PAREXEL is committed to easing these challenges for our customers. The Expert Office has been designed to provide customers with access to a global team of experts who work closely with them to develop customized strategies and oversee the optimal execution of trials. The Expert Office signals a truly new level of strategic partnering between PAREXEL and our customers,” said Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL International.
The Expert Office is comprised of top specialists in their fields, many of whom are former regulators, pharmaceutical company executives, and leaders of medical institutes, who draw on in-depth regulatory, business, and scientific experience. They address a spectrum of issues that may impact critical areas for customers such as study design, safety, patient recruitment, pricing, reimbursement, compliance, and approval. The team’s expertise spans Phase I - Phase IV clinical research and a broad range of therapeutic areas, including but not limited to oncology, cardiology, neurology, rheumatology, and infectious disease. The Expert Office draws upon the resources of PAREXEL’s experts worldwide as well as an external network of scientific advisors matched with the specific needs of each PAREXEL customer. These experts are integrated into PAREXEL’s Clinical Research Services offerings as part of study teams.
“Customers are increasingly looking to PAREXEL to provide insightful strategic guidance related to their compounds in development,” said Udo Kiessling, M.D., Corporate Vice President and Chief Medical Officer, who heads The Expert Office at PAREXEL. “Our thought leaders form a comprehensive, cohesive team that provides a strong relationship among medical practice, regulatory affairs, and clinical operations across a broad range of therapeutic areas. This consolidation of knowledge throughout the lifecycle of a program is focused on helping biopharmaceutical companies make faster, better informed development and commercialization decisions and accelerate clinical research.”
The Expert Office at PAREXEL offers capabilities such as:
PAREXEL draws on the breadth and depth of its expertise to help customers optimize development and increase global market access. For more information about The Expert Office at PAREXEL visit: http://www.PAREXEL.com/expertoffice/.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has over 9,130 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2009 as filed with the SEC on August 28, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXEL
International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com, or Gene
Carozza/Kim Baker of PAN Communications, +1-978-474-1900,
PAREXEL@pancomm.com
Web site: http://www.parexel.com/
